Galectin Begin Period Cash Flow from 2010 to 2025
| GALT Stock | USD 1.29 0.07 5.15% |
Begin Period Cash Flow | First Reported 2001-03-31 | Previous Quarter 25.6 M | Current Value 27.1 M | Quarterly Volatility 13.7 M |
Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 46 M, Interest Expense of 5.8 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0012 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.
Galectin | Begin Period Cash Flow |
Latest Galectin Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Galectin Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Galectin Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Galectin Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 17,895,133 | |
| Geometric Mean | 11,335,890 | |
| Coefficient Of Variation | 75.49 | |
| Mean Deviation | 11,028,758 | |
| Median | 15,362,000 | |
| Standard Deviation | 13,508,913 | |
| Sample Variance | 182.5T | |
| Range | 47.3M | |
| R-Value | 0.52 | |
| Mean Square Error | 141.8T | |
| R-Squared | 0.27 | |
| Significance | 0.04 | |
| Slope | 1,486,847 | |
| Total Sum of Squares | 2737.4T |
Galectin Begin Period Cash Flow History
About Galectin Therapeutics Financial Statements
Galectin Therapeutics shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 25.7 M | 13.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.